Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?


Drug Profile


Alternative Names: MSI-190; MSI-195; S-Adenosyl-L-Methionine; Sam-E; SAMe; Strada

Latest Information Update: 30 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MSI Methylation Sciences
  • Class Amino acids; Antidepressants; Nootropics
  • Mechanism of Action Beta adrenergic receptor modulators; Biogenic monoamine uptake modulators; Cytokine modulators; Muscarinic receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Major depressive disorder

Most Recent Events

  • 09 Jun 2017 Ademetionine is still at phase II development stage for Major depressive disorder in USA (PO) (MSI Methylation Sciences website, June 2017)
  • 06 Sep 2016 MSI Methylation Sciences plans a pivotal phase III programme for Major depressive disorder (Adjunctive treatment) in USA, European Union and Japan (MSI Methylation Sciences pipeline, September 2016)
  • 27 Jan 2016 Efficacy and adverse events data from the phase II trial in Major depressive disorder released by MSI Methylation Sciences
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top